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lavanol-Rich Cocoa
Promising New Dietary Intervention
o Reduce Cardiovascular Risk
n Type 2 Diabetes?*
mberto Campia, MD,
ulio A. Panza, MD, FACC
ashington, DC
therosclerotic cardiovascular disease represents the leading
ause of the morbidity and mortality associated with type 2
iabetes (1). Well-established epidemiological data indicate
hat diabetic patients have a risk of incident myocardial
nfarction and stroke twice as high as that of the general
opulation, with worse survival after their first event and
ubsequently increased mortality rates (2). Overall, approxi-
ately three-quarters of patients with type 2 diabetes mellitus
ill develop and possibly die of macrovascular disease, with a
ramatic loss of life expectancy, quality of life, and impact on
ealthcare costs (3,4). Encouraging clinical trial evidence sug-
ests that some of the available treatments for type 2 diabetes
nd an aggressive approach to risk factor reduction may
ecrease incident cardiovascular events and delay the onset of
omplications in diabetic patients (5). However, when com-
ared with the general population, the excess risk conferred by
iabetes has declined only marginally (6), partly because only a
inority of diabetic patients achieves the recommended levels
f control (3). Therefore, alternative approaches to the primary
nd secondary prevention of atherosclerosis in this population
re highly needed.
See page 2141
Given the impact of eating habits on cardiovascular
isease and the epidemiological evidence of protective
actors present in the diet of specific populations (7),
ignificant emphasis has recently been placed on the iden-
ification of dietary elements exerting beneficial effects on
he vasculature and on the elucidation of their molecular
echanism. The flavonoids, a ubiquitous class of plant-
erived polyphenols, have been proposed as likely candi-
ates, given the link between an increased dietary intake of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
From the Cardiovascular Research Institute at the Washington Hospital Center,
ashington, DC.hese phytochemicals and a reduction in cardiovascular
vents (8). The flavonoids comprise several distinct sub-
lasses, which are present in different concentrations in
arious foods, including, but not limited to, red wine, black
ea, onions, apples, and cocoa (9). While red wine and tea
ave attracted the initial focus of the scientific community,
nly in the last decade attention has been brought to the
avanol-rich cocoa. The interest in the effects of cocoa
ntake on the cardiovascular system was initially triggered by
he observation that the indigenous Kuna Indians, a popu-
ation living in an island off the coast of Panama, have a very
ow incidence of hypertension (10) and significantly lower
eath rates for ischemic heart disease, stroke, diabetes, and
ancer when compared with the Kuna Indians living in
rban Panama city (11). Among the potential factors
nderlying the differences between the 2 populations, di-
tary habits were found to be the most likely candidates. In
articular, the high intake of home-prepared cocoa, ex-
remely rich in flavanols, in the indigenous Kuna appeared
o confer a relevant protective effect (9). Numerous subse-
uent investigations have also confirmed the inverse relation
etween dietary cocoa, blood pressure, and cardiovascular
ortality in Western populations (12), and have laid the
oundation for studies aimed at elucidating the underlying
athophysiological mechanisms. Given the role of the
ndothelium in hypertension and atherosclerosis, research
fforts have focused on the acute and chronic effects of
avanol-rich cocoa on endothelial vasodilator function.
fter the initial report of strong peripheral nitric oxide
NO)-dependent vasodilation in healthy subjects (13),
avanol-rich cocoa has been shown to reverse endothelial
ysfunction, measured as flow-mediated dilation (FMD) of
he brachial artery, in smokers (14) and in hypertensive
atients (15). Of note, in the latter population, dark
hocolate also decreases low-density lipoprotein cholesterol,
owers blood pressure, and improves insulin sensitivity (15).
urthermore, in an intriguing study in heart transplant
ecipients, dark chocolate has been shown to improve
ndothelium-dependent responses in the coronary circula-
ion and to decrease shear stress-induced platelet adhesion
16), suggesting that flavanols may directly affect athero-
hrombosis. However, whether similar beneficial actions are
lso present in patients with type 2 diabetes is unknown.
In this issue of the Journal, Balzer et al. (17) address this lack
f knowledge by reporting the results of a study on the acute
nd chronic effects of flavanol-containing cocoa intake on the
ascular function of treated type 2 diabetic patients between
ges 50 and 80 years. The primary outcome measures were
hanges in FMD of the brachial artery, a well-established
oninvasive technique to assess NO-dependent endothelial
unction. The secondary outcomes included changes of the
lasma concentration of free flavanols (epicatechin, catechin),
nd their respective conjugated flavanol metabolites, measured
y high-pressure liquid chromatography. To overcome several
f the limitations of previous investigations, the authors first
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June 3, 2008:2150–2 Editorial Commentonducted a feasibility study on 10 patients to determine the
ppropriate dosing, assess safety and tolerability, and measure
he effect size of the intervention in order to calculate the
ppropriate sample size of the subsequent efficacy study. The
fficacy study was undertaken using a randomized, double-
asked, parallel-group design and included 44 patients ran-
omly allocated to a treatment group (321 mg of flavanols per
ose; 3 doses per day) or a control group (25 mg of flavanols
er dose; 3 doses per day). Each group ingested a single dose
f either treatment or control 3 times a day over a period of 30
ays. The authors assessed the acute effects, 2 h after ingestion
f the control or the cocoa drink, and the long-term effects, on
ays 8 and 30.
The authors report that, in the feasibility study population,
cute ingestion of the medium and high dose of flavanols
aused dose-dependent increases in plasma flavanol metabolite
evels and improved FMD by 44% (p  0.001). Importantly,
ndothelium-independent nitroglycerin-mediated dilation was
ot affected by any of the dietary interventions. In the efficacy
tudy, fasting plasma levels of flavanol metabolites increased by
6% on day 8 (p  0.01) and by 48% on day 30 (p  0.01).
he daily consumption of flavanol-containing cocoa by pa-
ients assigned to the treatment group resulted in consistent
ncreases in baseline FMD. The acute effects on FMD in the
reatment group were of similar effect size at study entry and
fter 8 and 30 days of regular cocoa intake. In accordance with
he finding of the feasibility study, nitroglycerin-mediated
ilation was similar between the 2 groups and was not affected
y the dietary interventions.
The results of this study answer several important ques-
ions. First, does the ingestion of flavanols result in a
ose-dependent and predictable increase in the plasma
evels of long-standing diabetic patients? Previous investi-
ations have shown that nutrients in the diet may not reach
hysiological levels in subjects with diabetes (18), possibly
econdary to abnormal gastrointestinal function (19).
herefore, a lack of effect of a dietary intervention would
ot necessarily be secondary to a lack of pharmacodynamic
ctivity. The data reported in this investigation indicate that
avanol intake in diabetic patients results in plasma levels
onsistent with those observed in nondiabetic subjects
14,15), suggesting that absorption of flavanols is not a
imiting factor in this population and that flavanol clearance
s not increased. Second, are the vascular effects biologically
elevant and sustained over time? The patient population of
his study had baseline FMD values that were lower than
he reference values measured in the same laboratory. After
he acute ingestion of a flavanol-rich cocoa drink, FMD
alues were normalized, indicating temporary reversal of
ndothelial dysfunction. Of note, in the treatment group,
aseline FMD increased steadily and the magnitude of the
cute effect was maintained over time, suggesting a lack of
ignificant desensitization or tolerance. Importantly, the
ascular responses to nitroglycerin administration were not
ffected by any of the interventions and remained constant
ver time, confirming the hypothesis that the changes inascular function are secondary to the effects of treatment on
ndothelial function and NO bioavailability.
In summary, this elegant investigation addresses many of
he reservations raised toward previous studies. The feasi-
ility study allowed the authors to determine the dose and
he appropriate sample size for the efficacy trial. Participants
ere carefully selected and represented a typical diabetic
opulation. The cocoa drinks were standardized and
atched for caloric, nutritional, caffeine, and theobromine
ontent and had similar taste. The results of the efficacy study
learly showed sustained effects of high flavanol cocoa intake
n vascular function over a period of 30 days.
These findings expand previous observations to patients
ith type 2 diabetes and represent a further step in our
nderstanding of the vascular effects of flavanol-rich cocoa.
owever, although endothelial function has been shown to
redict future cardiovascular events (20), randomized, large
cale clinical trials assessing relevant clinical outcomes are
ecessary before any recommendations are made regarding
ietary supplementation with flavanol-rich cocoa.
eprint requests and correspondence: Dr. Umberto Campia,
ashington Hospital Center, 100 Irving Street Northwest,
ast Building, Suite 5123, Washington, DC 20010. E-mail:
mberto.campia@medstar.net.
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